Substance abuse benzodiazepines

Benzodiazepines and other anxiolytics. Although benzodiazepines are widely used in the treatment of acute alcohol withdrawal, most nonmedical personnel involved in the treatment of alcoholism are opposed to the use of medications that can induce any variety of dependence to treat the anxiety, depression, and sleep disturbances that can persist for months following withdrawal. Researchers have debated the pros and cons of the use of benzodiazepines for the management of anxiety or insomnia in alcoholic patients and other substance abuse patients during the postwithdrawal period (Ciraulo and Nace 2000 Posternak and Mueller 2001). 

Ciraulo DA, Jaffe JH Tricyclic antidepressants in the treatment of depression associated with alcoholism. Clin Psychopharmacol 1 146—150, 1981 Ciraulo DA, Nace E Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 9 276—284, 2000 Ciraulo DA, Barnhill JG, Jaffe JH, et al Intravenous pharmacokinetics of 2-hydroxy-imipramine in alcoholics and normal controls. J StudAlcohol 51 366-372, 1990 Ciraulo DA, Knapp CM, LoCastro J, et al A benzodiazepine mood effect scale reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. Am J Drug Alcohol Abuse 27 339—347, 2001 Collins MA Tetrahydropapaveroline in Parkinson s disease and alcoholism a look back in honor of Merton Sandler. Neurotoxicology 25 117-120, 2004 COMBINE Study Research Group Testing combined pharmacotherapies and behavioral interventions in alcohol dependence rationale and methods. Alcohol Clin Exp Res 27 1107-1122, 2003a... 

In the absence of a diagnosis of substance abuse, most patients taking benzodiazepines continue to benefit ftom treatment over extended periods of... 

A dramatically different pattern is found in surveys of drug abuse treatment facilities. Substance abuse treatment centers have reported that more than 20% of patients use benzodiazepines weekly or more frequently, with 30%— 90% of opioid abusers reporting illicit use (Iguchi et al. 1993 Stitzer et al 1981). Methadone clinics reported that high proportions ofurine samples are positive for benzodiazepines (Darke et al. 2003 Dinwiddle et al. 1996 Ross and Darke 2000 Seivewright 2001 Strain et al. 1991 Williams et al. 1996). The reasons for the high rates of benzodiazepine use in opioid addicts include self-medication of insomnia, anxiety, and withdrawal symptoms, as well as attempts to boost the euphoric effects of opioids. 

Limited results from clinical laboratory evaluations suggested that the GABAj l agonists zaleplon (Rush et al. 1999b) and Zolpidem (Rush et al. 1999a) produce effects that are consistent with abuse potential comparable to that of the benzodiazepine triazolam. The reported incidence of dependence on Zolpidem in the medical literature is low, compared with that for benzodiazepines, and is characterized by use of high doses, often in individuals with a history of substance abuse (Hajak et al. 2003 Vartzopoulos et al. 2000). 

Benzodiazepines have a low risk for abuse in anxiety disorder patients without a history of alcohol or other substance abuse. Among the benzodiazepines there may be a spectrum of abuse liability, with drugs that serve as prodrugs for desmethyldiazepam (e.g., clorazepate), slow-onset agents (e.g., oxazepam), and partial agonists (e.g., abecarnil) having the least potential for abuse. However, there is no currently marketed benzodiazepine or related drug that is free of potential for abuse. 

Dependence on barbiturates has declined in recent years as physicians have substituted benzodiazepines for the treatment of many of the conditions for which barbiturates were formerly used. Clinicians will still see cases of abuse and dependence among medical patients receiving barbiturates or barbirurate combination products (e.g., Fiorinal) and in substance abusers (Silberstein and McCrory 2001). 

Ciraulo DA, Nace EP Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 9 276—284, 2000 Ciraulo DA, Barnhill JG, Greenblatt DJ, et al Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. J Clin Psychiatry 49 333—337, 1988a... 

Posternak MA, Mueller TI Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict 10 48-68, 2001... 

Side effects associated with benzodiazepines in PD patients are similar to those observed in other disorders. Sedation, fatigue, and cognitive impairment are the most commonly reported side effects.49 Benzodiazepines should be avoided in patients with current substance abuse, a history of such, dependence, or sleep apnea. Additionally, caution should be used in older adults because they have more pronounced psychomotor and cognitive effects. 

Benzodiazepines are used commonly in SAD however, there are limited data supporting their use. Clonazepam has been effective for social anxiety, fear, and phobic avoidance, and it reduced social and work disability during acute treatment.58 Long-term treatment is not desirable for many SAD patients owing to the risk of withdrawal and difficulty with discontinuation, cognitive side effects, and lack of effect on depressive symptoms. Benzodiazepines may be useful for acute relief of physiologic symptoms of anxiety when used concomitantly with antidepressants or psychotherapy. Benzodiazepines are contraindicated in SAD patients with alcohol or substance abuse or history of such. 

Taper oft antipsychotics, benzodiazepines, or sedative-hypnotic agents if possible Treat substance abuse... 

Serotonin-boosting antidepressants or longer-acting benzodiazepines are also both suitable first-line treatments for APD. For APD patients who are also troubled by depression, an antidepressant is obviously preferable. We also prefer to use antidepressants rather than benzodiazepines to treat APD patients who have a history of substance abuse. The current data suggests that any of the SSRls as well as nefazodone, mirtazapine, and venlafaxine may be helpful. When these do not work, a MAOI is a reasonable alternative provided the patient is willing to commit to the dietary regimen. 

Within this Held, most of the research and results have been focused on the effects of drug therapy on the disorders induced by alcohol, and by the abuse of opiates. For a broader discussion of substance abuse see Chapter 18. In all instances of alcohol or drug abuse the first objective is to wean the patients from the addictive substance, treating or preventing the effects of withdrawal for those substances which cause physical dependence (alcohol, nicotine, opiates, caffeine, certain psychotropic agents such as benzodiazepines, possibly antidepressants). The second phase is the prevention of recurrence or relapse, which relies on a combination of social support, psychotherapy, and pharmacotherapy where available. In this respect, alcoholism is exemplary. 

For those with a history of substance abuse or intolerance to benzodiazepines and the elderly, caution must be used in controlling anxiety. In these cases, benzodiazepines may exacerbate other conditions. Preliminary reports suggest that antipsychotics such as quetiapine may alleviate symptoms of anxiety. Other strategies include use of antihistamines such as hydroxyzine and diphenhydramine. 

The manner and severity of withdrawal symptoms varies according to the type of drug and the extent of physical dependence.50 Withdrawal after short-term benzodiazepine use may be associated with problems such as sleep disturbances (i.e., so-called rebound insomnia).34 62 As discussed earlier, withdrawal effects seem to be milder with the newer nonbenzodiazepine agents (zolpidem and zaleplon).34,62 Newer agents, however, are not devoid of these problems and care should be taken with prolonged use, especially in people with psychiatric disorders or a history of substance abuse.26... 

Hospital admissions due to benzodiazepine abuse have been studied as well. According to the Treatment Episode Data Set (TEDS) from the Substance Abuse and Mental Health Services Administration (SAMHSA) of the United States Department of Health and Human Services, tranquilizers such as the benzodiazepines were the primary substance of 0.3% of TEDS admissions in 1998. In addition, 39% of patients admitted for tranquilizer use reported abuse of alcohol as well as tranquilizers. Admissions for tranquilizer abuse were mostly female (48%) and white (90%). 

Lifetime use of benzodiazepines has decreased slighty over the years, but this reduction has been minimal. According to the results from an annual survey done by SAMSHA (Substance Abuse and Mental Health Services Administration, of the United States Department of Health), use of tranquilizers or benzodiazepines has decreased. Data from SAMSHA s 2000 National Household Survey on Drug Abuse shows that in persons aged 18-25, lifetime use of tranquilizers decreased from 7.9% in 1999 to 7.4% in 2000. Past year usage of tranquilizers in this age group also decreased, from 3.1% in 1999, to 3.0% in 2000. Finally, past month usage of tranquilizers in the 18 to 25-year-old respondents to the survey decreased, from 1.1% in 1999, to 1.0% in 2000. 

Overall, benzodiazepines are excellent agents when used in carefully selected patients, when use is preferably limited to short term (with some exceptions), and when use is systematically avoided in individuals with a documented history of substance abuse. 

The atypical antianxiety medication buspirone has been used with some success with GAD patients. This medication offers the benefits of reduced rumination and worry, but without the problems of sedation and potential drug dependence seen with benzodiazepines. Buspirone is not addictive and thus provides a treatment option for GAD patients with substance abuse risk. 

These symptoms usually are not directly treated with psychotropic medications. Rather the primary medical disorder is treated, or the patient is referred for treatment of a chemical dependency problem (see chapter 12). When psychotropics are employed, they generally are used for short periods of time. Medications of choice are the benzodiazepines (although they should be used with extreme caution in patients with a substance abuse disorder). 

In Hungary, sedative and benzodiazepine use accounted for 26 % of all treatment statistics in 1 998, and for 1 7.9 % in Romania in 1997. In Latvia in 1998, 34.2 % of all psychotropic substance use involved volatile substances, while sedatives accounted for 10.1 %. In Slovakia, the proportion of volatile substance users among all treated clients was 1 0 to 11 % between 1 994 and 1 998, while sedative use accounted for 6 % of all demands for treatment in 1998. A national survey of 15-year-olds conducted in 1995 in Slovenia found a significant percentage of glue and other substance abuse, as well as of tranquillisers, particularly among girls. 

---